Literature DB >> 18537937

Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.

Christophe Baudouin1.   

Abstract

Antiglaucoma medications are often associated with ocular adverse reactions such as dry eye, and burning or stinging sensations. These undesirable effects may lead to treatment discontinuation and reduced quality of life in patients with glaucoma. Antiglaucoma medications usually contain benzalkonium chloride (BAK) as a preservative. Animal studies, in vitro studies and in vivo experiments have demonstrated various adverse effects of BAK. Clinical studies have also shown an increased incidence of adverse events with BAK and have demonstrated that the withdrawal of preservatives reduces these effects. Collectively, these data suggest that preservative-free antiglaucoma treatments have clinically relevant benefits for patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537937     DOI: 10.1111/j.1755-3768.2008.01250.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  70 in total

1.  Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial.

Authors:  Arthur Shedden; Ingrid A Adamsons; Albert J Getson; Jean K Laurence; Christopher R Lines; David J Hewitt; Tony W Ho
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-02       Impact factor: 3.117

Review 2.  The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction.

Authors:  Gerd Geerling; Joseph Tauber; Christophe Baudouin; Eiki Goto; Yukihiro Matsumoto; Terrence O'Brien; Maurizio Rolando; Kazuo Tsubota; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

3.  Quality of life in glaucoma patients after selective laser trabeculoplasty.

Authors:  Myrjam De Keyser; Maya De Belder; Veva De Groot
Journal:  Int J Ophthalmol       Date:  2017-05-18       Impact factor: 1.779

4.  Barriers to Glaucoma Medication Compliance Among Veterans: Dry Eye Symptoms and Anxiety Disorders.

Authors:  Jack Stringham; Noy Ashkenazy; Anat Galor; Sarah R Wellik
Journal:  Eye Contact Lens       Date:  2018-01       Impact factor: 2.018

5.  A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension.

Authors:  David A Godfrey; Lee S Peplinski; Jeanette A Stewart; William C Stewart
Journal:  Clin Ophthalmol       Date:  2009-06-02

6.  Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model.

Authors:  Su Khoh-Reiter; Bart A Jessen
Journal:  BMC Ophthalmol       Date:  2009-07-28       Impact factor: 2.209

7.  Characteristics of respondents with glaucoma and dry eye in a national panel survey.

Authors:  Jordana K Schmier; David W Covert
Journal:  Clin Ophthalmol       Date:  2009-11-16

8.  First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results.

Authors:  Jordana K Schmier; David W Covert
Journal:  Clin Ophthalmol       Date:  2010-05-14

9.  Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis.

Authors:  Patricia B Williams; Elizabeth Crandall; John D Sheppard
Journal:  Clin Ophthalmol       Date:  2010-09-07

10.  First-year treatment costs among new initiators of topical prostaglandin analogs.

Authors:  Jordana K Schmier; David W Covert; Alan L Robin
Journal:  Clin Ophthalmol       Date:  2009-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.